Physician profile
Marion D Mclaughlin
NPI 1346245511
$1,862.87
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $653 · 2020: $814 · 2021: $396.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $295.39 | 2019-2021 | |
| Amgen INC. | $263.45 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $182.84 | 2019-2021 | |
| Lilly USA, LLC | $140.97 | 2019-2021 | |
| Abbvie INC. | $135.95 | 2020-2021 | |
| Novo Nordisk INC | $110.59 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.18 | 2019-2021 | |
| Astellas Pharma US INC | $95.15 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $78.64 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $58.66 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.34 | 2020 | |
| Amarin Pharma, INC. | $47.06 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $39.51 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $37.24 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $32.15 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $31.66 | 2020 | |
| Pfizer INC. | $26.01 | 2019 | |
| Daiichi Sankyo INC. | $24.95 | 2020-2021 | |
| Allergan, INC. | $24.70 | 2020 | |
| Avanir Pharmaceuticals, INC. | $14.22 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.74 | 2019 | |
| Shire North American Group INC | $11.52 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.43 | 2020 | |
| Eisai INC. | $11.26 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.26 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $10.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marion Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.